The Effect of Statins on the No-Reflow Phenomenon

No abstract is available for this paper.

• Publication year

  2012

• Venue

  American Journal of Cardiovascular Drugs

• Publication date

  2012-08-17

• Fields of study

  Medicine

• Identifiers
  DOI 10.2165/00129784-200909020-00002PMID 19331436
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pretreatment with simvastatin reduces myocardial no‐reflow by opening mitochondrial KATP channel

  2006cited by this paper
• Simvastatin and losartan enhance nitric oxide and reduce oxidative stress in salt-induced hypertension.

  2005cited by this paper
• Ischemic preconditioning attenuates capillary no-reflow and leukocyte adherence in postischemic pancreatitis

  2004cited by this paper
• Primary Percutaneous Coronary Intervention for Every Patient with ST-Segment Elevation Myocardial Infarction: What Stands in the Way?

  2004cited by this paper
• Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction.

  2003cited by this paper
• Clinical and angiographic correlates and outcomes of suboptimal coronary flow inpatients with acute myocardial infarction undergoing primary percutaneous coronary intervention.

  2003cited by this paper
• Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials.

  2003cited by this paper
• Diabetes and hyperglycemia impair activation of mitochondrial K(ATP) channels.

  2001cited by this paper
• HMG-CoA Reductase Inhibitors Improve Endothelial Dysfunction in Normocholesterolemic Hypertension via Reduced Production of Reactive Oxygen Species

  2001cited by this paper
• HMG‐CoA reductase inhibition protects the diabetic myocardium from ischemia‐reperfusion injury

  2001cited by this paper
• Predictive factors for development of the no-reflow phenomenon in patients with reperfused anterior wall acute myocardial infarction.

  2001cited by this paper
• Impaired glucose metabolism predicts mortality after a myocardial infarction.

  2001cited by this paper
• Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction.

  2001cited by this paper
• Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction.

  2000cited by this paper
• Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview.

  2000cited by this paper
• Diabetes abolishes ischemic preconditioning: role of glucose, insulin, and osmolality.

  2000cited by this paper
• Diabetes enhances leukocyte accumulation in the coronary microcirculation early in reperfusion following ischemia.

  2000cited by this paper
• Acute hyperglycemia abolishes ischemic preconditioning in vivo.

  1998cited by this paper
• Acute hyperglycemia abolishes ischemic preconditioning in vivo.

  1998cited by this paper
• Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction.

  1998cited by this paper
• Clinical implications of the 'no reflow' phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction.

  1996cited by this paper
• Predictors of in-hospital and 6-month outcome after acute myocardial infarction in the reperfusion era: the Primary Angioplasty in Myocardial Infarction (PAMI) trail.

  1995cited by this paper
• Thrombolysis in myocardial infarction (TIMI) trial: Phase I. A comparison between intravenous tissue plasminogen activator and intravenous streptokinase

  1988cited by this paper
• Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.

  1987cited by this paper
• Hyperglycaemia following Acute Myocardial Infarction: The Contribution of Undiagnosed Diabetes

  1987cited by this paper
• Thrombolysis inMyocardial Infarction (TIMI) Trial, Phase I:acomparison between intravenous tissue plasminogen activator andintravenous streptokinase*

  1987cited by this paper
• Prevalence and risks of hyperglycaemia and undiagnosed diabetes in patients with acute myocardial infarction.

  1984cited by this paper

• Influence of Stent Length on Periprocedural Outcomes After Primary Percutaneous Coronary Intervention in Patients with ST Segment Elevation Myocardial Infarction

  2022cites this paper
• Relationship between hyperglycaemia at admission and prognosis in patients with acute myocardial infarction: a retrospective cohort study

  2022cites this paper
• The No-reflow Phenomenon: Is it Predictable by Demographic factors and Routine Laboratory Data?

  2021influential citation
• Clinical, Laboratory, and Procedural Predictors of No-Reflow in Patients Undergoing Primary Percutaneous Coronary Intervention

  2020cites this paper
• Coronary plaque redistribution after stent implantation is determined by lipid composition: A NIRS-IVUS analysis.

  2018cites this paper
• Long-term clinical outcomes of transient and persistent no-reflow following percutaneous coronary intervention (PCI): a multicentre Australian registry.

  2018cites this paper
• Effect of chronic pretreatment with beta-blockers on no-reflow phenomenon in diabetic patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention

  2017influential citation
• Impact of Previous Stroke on Short-Term Myocardial Reinfarction in Patients With Acute ST Segment Elevation Myocardial Infarction

  2016cites this paper
• Coronary No-Reflow Following Percutaenous Coronary Intervention

  2013cites this paper
• Effect of Statin Pretreatment on Myocardial Perfusion in Patients Undergoing Primary Percutaneous Coronary Intervention: A Systematic Review and Meta‐analysis

  2013cites this paper
• Effect of pre‐procedural statin therapy on myocardial no‐reflow following percutaneous coronary intervention: a meta analysis

  2013cites this paper
• Microvascular Coronary Dysfunction Post–Myocardial Revascularization

  2013cites this paper
• Effect of chronic pretreatment of angiotensin-converting receptor blocker on no-reflow phenomenon in patients with acute myocardial infarction undergoing percutaneous coronary intervention.

  2013cites this paper
• Acute hyperglycemia causes microvascular damage, leading to poor functional recovery and remodeling in patients with reperfused ST-segment elevation myocardial infarction

  2012cites this paper
• Evolution and future perspectives for cardiovascular interventions in China.

  2012cites this paper
• Flow-dependent endothelial function and kidney dysfunction.

  2012cites this paper